FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $415,647 | -83.4% | 41,194 | -63.1% | 0.25% | -82.7% |
| Q3 2022 | $2,500,000 | -15.1% | 111,545 | -6.1% | 1.43% | -19.6% |
| Q2 2022 | $2,943,000 | +17.4% | 118,778 | +83.7% | 1.78% | +11.5% |
| Q1 2022 | $2,507,000 | +85.7% | 64,665 | +180.2% | 1.59% | +48.3% |
| Q4 2021 | $1,350,000 | +32.9% | 23,081 | +34.7% | 1.08% | +60.0% |
| Q3 2021 | $1,016,000 | +5.2% | 17,134 | +54.0% | 0.67% | -1.9% |
| Q2 2021 | $966,000 | +75.0% | 11,128 | -19.4% | 0.68% | +70.4% |
| Q3 2020 | $552,000 | +29.0% | 13,807 | +10.8% | 0.40% | +13.6% |
| Q2 2020 | $428,000 | – | 12,463 | – | 0.35% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |